<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02043379</url>
  </required_header>
  <id_info>
    <org_study_id>F13114002</org_study_id>
    <secondary_id>F13114002</secondary_id>
    <nct_id>NCT02043379</nct_id>
  </id_info>
  <brief_title>Post-bypass Prophylactic IVIG in Infants and Neonates</brief_title>
  <official_title>Intravenous Immunoglobulin for Early Prevention of Cardiopulmonary Bypass Induced Hypogammaglobulinemia in Infants and Neonates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Grifols Biologicals Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study protocol is to determine if administering Intravenous
      Immunoglobulin (IVIG) for treatment of cardiopulmonary bypass (CPB) induced
      hypogammaglobulinemia in the early post-operative period can impact post-surgical outcomes
      (i.e., infection, fluid overload, and associated morbidities).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The intense post-CPB systemic inflammatory response syndrome (SIRS) is well described in
      neonates and infants. Increased production and release of pro-inflammatory cytokines,
      including Tumor Necrosis Factor, Interleukin1-B, and Interleukin-6 may suppress myocardial
      contractility, induce capillary leak, and activate complement and the clotting cascade -
      together leading to potential organ injury and death. SIRS is also frequently accompanied by
      impairment of the humoral immune response. One potential reason for this acquired
      immunodeficiency after cardiac surgery is the removal of immunoglobulins (Ig)s from the
      vascular space into other compartments where they are either sequestered or lost from the
      body altogether. We recently demonstrated that such Ig depletion from the intravascular
      compartment occurs in neonates following cardiac surgery. In a retrospective study of 53
      children &lt;3 months of age, we showed that plasma Immunoglobulin G (IgG) concentration drops
      precipitously after cardiac surgery and does not return to preoperative levels by 7 days; 51%
      of patients had hypogammaglobulinemia.

      An important question is whether post-CPB low IgG has clinical consequence. IgG plays an
      essential role in the humoral immune system, activating complement and inducing the
      phagocytic system to neutralize pathogens. IgG deficiency is a known risk factor for
      infections in other pediatric populations. We were the first to demonstrate that post-CPB
      hypogammaglobulinemia is associated with worse clinical outcomes, including increased
      secondary infections (37% vs.12% in those without low IgG, p&lt;0.05). These novel findings are
      paramount in that they identify a potential modifiable risk factor to improve outcomes after
      pediatric cardiac surgery with CPB. Additionally, low IgG is accompanied by fluid overload
      and prolonged mechanical ventilation. Igs constitute an important component of plasma oncotic
      pressure, so hypogammaglobulinemia may exacerbate anasarca, prolonging postoperative
      convalescence and increasing the morbidities associated with increased ICU length of stay.9

      Igs have an increasingly recognized role in modulating the innate immune response. Present
      use of IVIG exceeds mere antibody replacement and extends to the treatment of autoimmune and
      inflammatory conditions. In fact, more than 75% of IVIG use in the U.S. today is for the
      treatment of inflammatory conditions, where proposed mechanisms include reduction of
      pro-inflammatory cytokine and adhesion molecule expression, superantigen neutralization,
      restoration of glucocorticoid responsiveness, and blockade of complement fragment deposition.
      It is plausible that IVIG could benefit neonates after cardiac surgery not only via
      restoration of humoral opsonization capacity, but also as a modulator of innate immunity and
      SIRS. According to this model, tissue injury, CPB, and shock trigger SIRS, leading to
      hypogammaglobulinemia and resultant increased susceptibility to inflammatory dysregulation
      which might be ameliorated via administration of IVIG.

      In an adult study, IVIG failed to benefit postoperative cardiac patients with severe SIRS.
      However, the dose of IVIG given was relatively small compared with that typically given for
      autoimmune and inflammatory conditions. Neonates and infants may be more susceptible to the
      harmful effects of acquired hypogammaglobulinemia than adults as they may be unable to
      generate adequate quantities of antibodies in response to pathogens, relying mainly on
      maternal Igs until around the 4th to 6th month of life. In addition, they display an
      exaggerated inflammatory response to CPB as compared with older children and adults, so they
      might stand to benefit more from IVIG as an immunomodulator.

      Because of the increased vulnerability to acquired infection and other morbidities in the
      setting of hypogammaglobulinemia as result of enhanced SIRS and immune dysfunction, it is
      feasible that normalization of IgG concentration in the neonatal and infant population may
      improve clinical outcomes via restoration of the humoral immune system, modulation of the
      innate immune system, and restoration of intravascular oncotic pressure. The appropriate IgG
      level threshold for treatment and optimal plasma IgG level to target after administration of
      IVIG are presently unknown.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-Operative Infections</measure>
    <time_frame>until Hospital Discharge, an average of 30 days</time_frame>
    <description>The primary endpoint of this study is incidence of post-operative infections through hospital discharge</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-operative Infection</measure>
    <time_frame>within 1 week of surgery</time_frame>
    <description>Any positive culture or treatment for culture negative sepsis within 1 week of surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Stream Infection</measure>
    <time_frame>until Hospital Discharge, an average of 30 days</time_frame>
    <description>Any positive blood culture during the post-operative period until hospital discharge</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Stream Infection Within 1 Week of Surgery</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-operative Plasma Albumin</measure>
    <time_frame>up to 48 hours post CPB</time_frame>
    <description>Plasma albumin will be assessed at 24 and 48 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluid Overload Variables</measure>
    <time_frame>0-24 hours post-CPB</time_frame>
    <description>The following fluid overload variables will be assessed in milliliters per kilogram at 0-24 hours post-cardiopulmonary bypass: blood product and albumin administration, chest tube output, urine output, peritoneal dialysis output, net fluid balance, and percent fluid overload. The total output the subject's produce (urine, chest tube, peritoneal drainage, etc.) will be subtracted from the total input (medications, blood products, albumin administration, etc) to determine the total fluid intake in milliliters. This total number will then be divided by the subject's weight in kilograms to determine the fluid overload in mL/kg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative Inotrope Score</measure>
    <time_frame>first 48 hours post-CPB</time_frame>
    <description>The average admit, 12 hour, 24 hour, and 48 hour post-operative inotrope score will be calculated excluding Milrinone. To calculate the inotrope score the following formula was used: (Epinephrine/Norepinephrine dose in mcg/kg/min x 100) + (Dopamine dose in mcg/kg/min x 1) + (Phenylephrine dose in mcg/kg/min x 10) + (Vasopressin dose unit/kg/hr x 60/10000). The higher the inotrope score the more cardiac support the subject requires. There is not a &quot;normal&quot; scale or range used for this calculation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Variables</measure>
    <time_frame>until Hospital Discharge, an average of 30 days</time_frame>
    <description>Alive, ventilator free days will be recorded at hospital discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Discharge</measure>
    <time_frame>Approximately 1 month</time_frame>
    <description>From admit post-operative to the Pediatric cardiac intensive care unit until discharge from the hospital in days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Immunoglobulins</measure>
    <time_frame>5 days post-op</time_frame>
    <description>Plasma Immunoglobulin levels will be checked pre-operatively, 12 hours post-op and 5 days post-op</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interferon-gamma Plasma Cytokine Levels</measure>
    <time_frame>Pre-operative to 48 hours post-operative</time_frame>
    <description>Plasma cytokine levels measured preoperatively, 0, 4, 12, 24 hours, and 48 hours post-operatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunoglobulin Concentration in Chest Tube Drainage</measure>
    <time_frame>24 hours post-op</time_frame>
    <description>Immunoglobulin concentration will be measured from chest tube every 4 hours for first 12 hours post-operative and then 24 hours post-operative.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Approximately 1 month</time_frame>
    <description>Incidence of mortality from admit to Pediatric cardiac intensive care unit post-operatively until hospital discharge .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive Care Unit Length of Stay</measure>
    <time_frame>1 month</time_frame>
    <description>The length of stay in the pediatric cardiac intensive care unit from admit post-operative until either discharge home, discharge to another unit/hospital/care facility, or death. This value is calculated in hours. Admit post-operative is recorded as hour 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluid Overload Variables</measure>
    <time_frame>0-48 hours post-CPB</time_frame>
    <description>The following fluid overload variables will be assessed at 0-24 hours, 25-48 hours, and 0-48 hours post-cardiopulmonary bypass: blood product and albumin administration, chest tube output, urine output, peritoneal dialysis output, net fluid balance, and percent fluid overload.The total output the subject's produce (urine, chest tube, peritoneal drainage, etc.) will be subtracted from the total input (medications, blood products, albumin administration, etc) to determine the total fluid intake in milliliters. This total number will then be divided by the subject's weight in kilograms to determine the fluid overload in mL/kg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Variables</measure>
    <time_frame>until extubation, an average of 2 days</time_frame>
    <description>Time until first extubation in hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Variables</measure>
    <time_frame>until extubation, an average of 2 days</time_frame>
    <description>Total time duration of post-operative length of mechanical ventilation until hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-10 Plasma Cytokine Levels</measure>
    <time_frame>pre-operative through 48 hours post-operative</time_frame>
    <description>Plasma cytokine levels measured preoperatively, 0, 4, 12, 24 hours, and 48 hours post-operatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-12p70 Plasma Cytokine Levels</measure>
    <time_frame>pre-operative through 48 hours post-operative</time_frame>
    <description>Plasma cytokine levels measured preoperatively, 0, 4, 12, 24 hours, and 48 hours post-operatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-1b Plasma Cytokine Levels</measure>
    <time_frame>pre-operative through 48 hours post-operative</time_frame>
    <description>Plasma cytokine levels measured preoperatively, 0, 4, 12, 24 hours, and 48 hours post-operatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-6 Plasma Cytokine Levels</measure>
    <time_frame>pre-operative through 48 hours post-operative</time_frame>
    <description>Plasma cytokine levels measured preoperatively, 0, 4, 12, 24 hours, and 48 hours post-operatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-8 Plasma Cytokine Levels</measure>
    <time_frame>pre-operative through 48 hours post-operative</time_frame>
    <description>Plasma cytokine levels measured preoperatively, 0, 4, 12, 24 hours, and 48 hours post-operatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Necrosis Factor Plasma Cytokine Levels</measure>
    <time_frame>pre-operative through 48 hours post-operative</time_frame>
    <description>Plasma cytokine levels measured preoperatively, 0, 4, 12, 24 hours, and 48 hours post-operatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunoglobulin Concentration in Peritoneal Dialysis Drainage</measure>
    <time_frame>24 hours post-op</time_frame>
    <description>Immunoglobulin concentration will be measured from chest tube and peritoneal drain every 4 hours for first 12 hours post-operative and 24 hours post-operative.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Creatinine</measure>
    <time_frame>48 hours</time_frame>
    <description>Pre-operative and 48 hour post-operative maximum creatinine recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lactic Acid</measure>
    <time_frame>pre-operative through 24 hours post-operative</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Hypogammaglobulinemia</condition>
  <condition>Congenital Heart Disease</condition>
  <arm_group>
    <arm_group_label>IVIG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Those randomized to the study arm will receive a dose of IVIG 1 gram/kg at 12 hours post-cardiopulmonary bypass. This is a one time only dose and will be administered per hospital standards for IVIG administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subject's randomized into the placebo arm of the study will receive a volume of normal saline that is comparative to that if they were to receive IVIG. This will be at 12 hours post-cardiopulmonary bypass. This volume is to ensure blinding of study drug. This infusion will be administered as if the subject is receiving IVIG according to hospital policy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IVIG</intervention_name>
    <description>Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.</description>
    <arm_group_label>IVIG</arm_group_label>
    <other_name>Gamunex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.</description>
    <arm_group_label>Normal Saline</arm_group_label>
    <other_name>Normal Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infants &lt;6 months old

          -  Successfully weaned off cardiopulmonary bypass after cardiac surgery

        Exclusion Criteria:

          -  Requirement of extra corporeal membrane oxygenation in the operating room

          -  Known immune deficiency

          -  Current Do Not Resuscitate or limitation of care order

          -  Current enrollment in another interventional clinical study

          -  Refusal of parental consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Alten, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham Pediatric Cardiac Critical Care</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2014</study_first_submitted>
  <study_first_submitted_qc>January 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2014</study_first_posted>
  <results_first_submitted>October 14, 2016</results_first_submitted>
  <results_first_submitted_qc>March 1, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 13, 2017</results_first_posted>
  <last_update_submitted>March 1, 2017</last_update_submitted>
  <last_update_submitted_qc>March 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Jeffrey Alten, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>congenital heart disease</keyword>
  <keyword>Cardiopulmonary Bypass</keyword>
  <keyword>Hypogammaglobulinemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Agammaglobulinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD will not be shared with other individuals</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>IVIG</title>
          <description>Those randomized to the study arm will receive a dose of IVIG 1 gram/kg at 12 hours post-cardiopulmonary bypass. This is a one time only dose.
IVIG: Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.</description>
        </group>
        <group group_id="P2">
          <title>Normal Saline</title>
          <description>Subject's randomized into the placebo arm of the study will receive a volume of normal saline that is comparative to that if they were to receive IVIG. This will be at 12 hours post-cardiopulmonary bypass. This volume is to ensure blinding of study drug.
Placebo: If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IVIG</title>
          <description>Those randomized to the study arm will receive a dose of IVIG 1 gram/kg at 12 hours post-cardiopulmonary bypass. This is a one time only dose.
IVIG: Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.</description>
        </group>
        <group group_id="B2">
          <title>Normal Saline</title>
          <description>Subject's randomized into the placebo arm of the study will receive a volume of normal saline that is comparative to that if they were to receive IVIG. This will be at 12 hours post-cardiopulmonary bypass. This volume is to ensure blinding of study drug.
Placebo: If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9" lower_limit="6" upper_limit="50.75"/>
                    <measurement group_id="B2" value="47" lower_limit="6.25" upper_limit="79.5"/>
                    <measurement group_id="B3" value="11.5" lower_limit="6" upper_limit="74.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.45" lower_limit="3.17" upper_limit="3.99"/>
                    <measurement group_id="B2" value="3.85" lower_limit="3.04" upper_limit="4.52"/>
                    <measurement group_id="B3" value="3.51" lower_limit="3.13" upper_limit="4.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gestational Age</title>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" lower_limit="37" upper_limit="39"/>
                    <measurement group_id="B2" value="38.5" lower_limit="37" upper_limit="39.75"/>
                    <measurement group_id="B3" value="38" lower_limit="37" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>STAT category</title>
          <description>The Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery) Congenital Heart Surgery Mortality Categories. The STAT Mortality Categories range from 1 to 5 with higher values indicating greater risk of mortality associated with operations for congenital heart disease</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cardiopulmonyar bypass time</title>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105.5" lower_limit="73.5" upper_limit="120.3"/>
                    <measurement group_id="B2" value="91.5" lower_limit="68" upper_limit="122.3"/>
                    <measurement group_id="B3" value="97.5" lower_limit="70.5" upper_limit="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Aortic cross clamp time</title>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" lower_limit="42.5" upper_limit="70"/>
                    <measurement group_id="B2" value="56" lower_limit="44.5" upper_limit="78.5"/>
                    <measurement group_id="B3" value="53.5" lower_limit="44.5" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Intubated Pre-operatively</title>
          <description>Subjects requiring mechanical ventilation in the pre-operative period for either respiratory or cardiac support.</description>
          <units>subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Post-Operative Infections</title>
        <description>The primary endpoint of this study is incidence of post-operative infections through hospital discharge</description>
        <time_frame>until Hospital Discharge, an average of 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IVIG</title>
            <description>Those randomized to the study arm will receive a dose of IVIG 1 gram/kg at 12 hours post-cardiopulmonary bypass. This is a one time only dose.
IVIG: Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Subject's randomized into the placebo arm of the study will receive a volume of normal saline that is comparative to that if they were to receive IVIG. This will be at 12 hours post-cardiopulmonary bypass. This volume is to ensure blinding of study drug.
Placebo: If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-Operative Infections</title>
          <description>The primary endpoint of this study is incidence of post-operative infections through hospital discharge</description>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>We used alpha level of 0.05 and power of 0.8 to calculate the sample size necessary to detect a meaningful clinical difference for our primary endpoint.</non_inferiority_desc>
            <p_value>1</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Post-operative Infection</title>
        <description>Any positive culture or treatment for culture negative sepsis within 1 week of surgery</description>
        <time_frame>within 1 week of surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IVIG</title>
            <description>Those randomized to the study arm will receive a dose of IVIG 1 gram/kg at 12 hours post-cardiopulmonary bypass. This is a one time only dose.
IVIG: Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Subject's randomized into the placebo arm of the study will receive a volume of normal saline that is comparative to that if they were to receive IVIG. This will be at 12 hours post-cardiopulmonary bypass. This volume is to ensure blinding of study drug.
Placebo: If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-operative Infection</title>
          <description>Any positive culture or treatment for culture negative sepsis within 1 week of surgery</description>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation.</non_inferiority_desc>
            <p_value>1</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood Stream Infection</title>
        <description>Any positive blood culture during the post-operative period until hospital discharge</description>
        <time_frame>until Hospital Discharge, an average of 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IVIG</title>
            <description>Those randomized to the study arm will receive a dose of IVIG 1 gram/kg at 12 hours post-cardiopulmonary bypass. This is a one time only dose.
IVIG: Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Subject's randomized into the placebo arm of the study will receive a volume of normal saline that is comparative to that if they were to receive IVIG. This will be at 12 hours post-cardiopulmonary bypass. This volume is to ensure blinding of study drug.
Placebo: If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Stream Infection</title>
          <description>Any positive blood culture during the post-operative period until hospital discharge</description>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation.</non_inferiority_desc>
            <p_value>0.38</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood Stream Infection Within 1 Week of Surgery</title>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IVIG</title>
            <description>Those randomized to the study arm will receive a dose of IVIG 1 gram/kg at 12 hours post-cardiopulmonary bypass. This is a one time only dose.
IVIG: Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Subject's randomized into the placebo arm of the study will receive a volume of normal saline that is comparative to that if they were to receive IVIG. This will be at 12 hours post-cardiopulmonary bypass. This volume is to ensure blinding of study drug.
Placebo: If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Stream Infection Within 1 Week of Surgery</title>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation.</non_inferiority_desc>
            <p_value>0.26</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-operative Plasma Albumin</title>
        <description>Plasma albumin will be assessed at 24 and 48 hours.</description>
        <time_frame>up to 48 hours post CPB</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IVIG</title>
            <description>Those randomized to the study arm will receive a dose of IVIG 1 gram/kg at 12 hours post-cardiopulmonary bypass. This is a one time only dose.
IVIG: Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Subject's randomized into the placebo arm of the study will receive a volume of normal saline that is comparative to that if they were to receive IVIG. This will be at 12 hours post-cardiopulmonary bypass. This volume is to ensure blinding of study drug.
Placebo: If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-operative Plasma Albumin</title>
          <description>Plasma albumin will be assessed at 24 and 48 hours.</description>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 hour post-op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="0.74"/>
                    <measurement group_id="O2" value="4.1" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hour post-op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="0.57"/>
                    <measurement group_id="O2" value="3.6" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>24 hour post-CPB albumin</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.42</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>48 hour post CPB albumin</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.06</p_value>
            <p_value_desc>a p-value of &lt;0.05 represents the threshold for test signficance</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fluid Overload Variables</title>
        <description>The following fluid overload variables will be assessed in milliliters per kilogram at 0-24 hours post-cardiopulmonary bypass: blood product and albumin administration, chest tube output, urine output, peritoneal dialysis output, net fluid balance, and percent fluid overload. The total output the subject's produce (urine, chest tube, peritoneal drainage, etc.) will be subtracted from the total input (medications, blood products, albumin administration, etc) to determine the total fluid intake in milliliters. This total number will then be divided by the subject's weight in kilograms to determine the fluid overload in mL/kg.</description>
        <time_frame>0-24 hours post-CPB</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IVIG</title>
            <description>Those randomized to the study arm will receive a dose of IVIG 1 gram/kg at 12 hours post-cardiopulmonary bypass. This is a one time only dose.
IVIG: Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Subject's randomized into the placebo arm of the study will receive a volume of normal saline that is comparative to that if they were to receive IVIG. This will be at 12 hours post-cardiopulmonary bypass. This volume is to ensure blinding of study drug.
Placebo: If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.</description>
          </group>
        </group_list>
        <measure>
          <title>Fluid Overload Variables</title>
          <description>The following fluid overload variables will be assessed in milliliters per kilogram at 0-24 hours post-cardiopulmonary bypass: blood product and albumin administration, chest tube output, urine output, peritoneal dialysis output, net fluid balance, and percent fluid overload. The total output the subject's produce (urine, chest tube, peritoneal drainage, etc.) will be subtracted from the total input (medications, blood products, albumin administration, etc) to determine the total fluid intake in milliliters. This total number will then be divided by the subject's weight in kilograms to determine the fluid overload in mL/kg.</description>
          <units>mililiters/kilogram</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="0.6" upper_limit="74"/>
                    <measurement group_id="O2" value="58.1" lower_limit="34.4" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation.</non_inferiority_desc>
            <p_value>0.52</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-operative Inotrope Score</title>
        <description>The average admit, 12 hour, 24 hour, and 48 hour post-operative inotrope score will be calculated excluding Milrinone. To calculate the inotrope score the following formula was used: (Epinephrine/Norepinephrine dose in mcg/kg/min x 100) + (Dopamine dose in mcg/kg/min x 1) + (Phenylephrine dose in mcg/kg/min x 10) + (Vasopressin dose unit/kg/hr x 60/10000). The higher the inotrope score the more cardiac support the subject requires. There is not a &quot;normal&quot; scale or range used for this calculation.</description>
        <time_frame>first 48 hours post-CPB</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IVIG</title>
            <description>Those randomized to the study arm will receive a dose of IVIG 1 gram/kg at 12 hours post-cardiopulmonary bypass. This is a one time only dose.
IVIG: Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Subject's randomized into the placebo arm of the study will receive a volume of normal saline that is comparative to that if they were to receive IVIG. This will be at 12 hours post-cardiopulmonary bypass. This volume is to ensure blinding of study drug.
Placebo: If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-operative Inotrope Score</title>
          <description>The average admit, 12 hour, 24 hour, and 48 hour post-operative inotrope score will be calculated excluding Milrinone. To calculate the inotrope score the following formula was used: (Epinephrine/Norepinephrine dose in mcg/kg/min x 100) + (Dopamine dose in mcg/kg/min x 1) + (Phenylephrine dose in mcg/kg/min x 10) + (Vasopressin dose unit/kg/hr x 60/10000). The higher the inotrope score the more cardiac support the subject requires. There is not a &quot;normal&quot; scale or range used for this calculation.</description>
          <units>inotropic score</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Admit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="3.23" upper_limit="7.95"/>
                    <measurement group_id="O2" value="4.5" lower_limit="3.15" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hr post-op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="3.25" upper_limit="7.68"/>
                    <measurement group_id="O2" value="5.3" lower_limit="3" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hr post-op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="3.3" upper_limit="7.3"/>
                    <measurement group_id="O2" value="5.8" lower_limit="3.18" upper_limit="6.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hr post-op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" lower_limit="3.08" upper_limit="7.83"/>
                    <measurement group_id="O2" value="2" lower_limit="1" upper_limit="6.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Admit Inotrope Score</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation.</non_inferiority_desc>
            <p_value>0.81</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>12 hours post-operative inotrope score</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.82</p_value>
            <p_value_desc>a p value of &lt;0.05 represents the threshold for statistical significance</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>24 hours post-operative inotrope score</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.9</p_value>
            <p_value_desc>a p value of &lt;0.05 represents the threshold for statistical significance</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>48 hours post-operative inotrope score</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.23</p_value>
            <p_value_desc>a p-value of &lt;0.05 represents the threshold for statistical signficance</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Respiratory Variables</title>
        <description>Alive, ventilator free days will be recorded at hospital discharge.</description>
        <time_frame>until Hospital Discharge, an average of 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IVIG</title>
            <description>Those randomized to the study arm will receive a dose of IVIG 1 gram/kg at 12 hours post-cardiopulmonary bypass. This is a one time only dose.
IVIG: Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Subject's randomized into the placebo arm of the study will receive a volume of normal saline that is comparative to that if they were to receive IVIG. This will be at 12 hours post-cardiopulmonary bypass. This volume is to ensure blinding of study drug.
Placebo: If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.</description>
          </group>
        </group_list>
        <measure>
          <title>Respiratory Variables</title>
          <description>Alive, ventilator free days will be recorded at hospital discharge.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.7" lower_limit="21.1" upper_limit="26.3"/>
                    <measurement group_id="O2" value="25.5" lower_limit="21.6" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation.</non_inferiority_desc>
            <p_value>0.49</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Discharge</title>
        <description>From admit post-operative to the Pediatric cardiac intensive care unit until discharge from the hospital in days.</description>
        <time_frame>Approximately 1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IVIG</title>
            <description>Those randomized to the study arm will receive a dose of IVIG 1 gram/kg at 12 hours post-cardiopulmonary bypass. This is a one time only dose.
IVIG: Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Subject's randomized into the placebo arm of the study will receive a volume of normal saline that is comparative to that if they were to receive IVIG. This will be at 12 hours post-cardiopulmonary bypass. This volume is to ensure blinding of study drug.
Placebo: If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Discharge</title>
          <description>From admit post-operative to the Pediatric cardiac intensive care unit until discharge from the hospital in days.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" lower_limit="11.25" upper_limit="35"/>
                    <measurement group_id="O2" value="22" lower_limit="7.25" upper_limit="34.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation.</non_inferiority_desc>
            <p_value>0.79</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Immunoglobulins</title>
        <description>Plasma Immunoglobulin levels will be checked pre-operatively, 12 hours post-op and 5 days post-op</description>
        <time_frame>5 days post-op</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IVIG</title>
            <description>Those randomized to the study arm will receive a dose of IVIG 1 gram/kg at 12 hours post-cardiopulmonary bypass. This is a one time only dose.
IVIG: Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Subject's randomized into the placebo arm of the study will receive a volume of normal saline that is comparative to that if they were to receive IVIG. This will be at 12 hours post-cardiopulmonary bypass. This volume is to ensure blinding of study drug.
Placebo: If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Immunoglobulins</title>
          <description>Plasma Immunoglobulin levels will be checked pre-operatively, 12 hours post-op and 5 days post-op</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-operative serum IgG level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="487" spread="226.1"/>
                    <measurement group_id="O2" value="414" spread="230.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hour post-operative serum IgG level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="496" spread="183"/>
                    <measurement group_id="O2" value="569" spread="272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-operative day 3 serum IgG level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="837" spread="243"/>
                    <measurement group_id="O2" value="508" spread="215.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-operative day 5 serum IgG level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="839" spread="213"/>
                    <measurement group_id="O2" value="585" spread="212.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>pre-operative IgG level</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation.</non_inferiority_desc>
            <p_value>0.32</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>12 hours post-operative IgG level</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.36</p_value>
            <p_value_desc>a p-value of &lt;0.05 represents the threshold for statistical significance</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>post-operative day 3 (72 hours) IgG level</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>&lt;0.01</p_value>
            <p_value_desc>p-value of &lt;0.05 represents the threshold for statistical signficance</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>post-operative day 5 (120 hours) IgG level</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>&lt;0.01</p_value>
            <p_value_desc>p-value of &lt;0.05 represents the threshold for statistical significance</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interferon-gamma Plasma Cytokine Levels</title>
        <description>Plasma cytokine levels measured preoperatively, 0, 4, 12, 24 hours, and 48 hours post-operatively.</description>
        <time_frame>Pre-operative to 48 hours post-operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IVIG</title>
            <description>Those randomized to the study arm will receive a dose of IVIG 1 gram/kg at 12 hours post-cardiopulmonary bypass. This is a one time only dose.
IVIG: Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Subject's randomized into the placebo arm of the study will receive a volume of normal saline that is comparative to that if they were to receive IVIG. This will be at 12 hours post-cardiopulmonary bypass. This volume is to ensure blinding of study drug.
Placebo: If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.</description>
          </group>
        </group_list>
        <measure>
          <title>Interferon-gamma Plasma Cytokine Levels</title>
          <description>Plasma cytokine levels measured preoperatively, 0, 4, 12, 24 hours, and 48 hours post-operatively.</description>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-operative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="0.7" upper_limit="4.5"/>
                    <measurement group_id="O2" value="3.5" lower_limit="2.5" upper_limit="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 hour post-op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="1.3" upper_limit="4.2"/>
                    <measurement group_id="O2" value="6" lower_limit="3.4" upper_limit="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hour post-op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="2.2" upper_limit="4.1"/>
                    <measurement group_id="O2" value="6.1" lower_limit="3" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hour post-op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="2" upper_limit="4.5"/>
                    <measurement group_id="O2" value="6.3" lower_limit="2.6" upper_limit="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hour post-op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1.3" upper_limit="3.2"/>
                    <measurement group_id="O2" value="5.6" lower_limit="2.7" upper_limit="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hour post-op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="1.4" upper_limit="3.2"/>
                    <measurement group_id="O2" value="3.4" lower_limit="2.3" upper_limit="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>pre-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.60</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>0 hour post-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.06</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>4 hour post-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.06</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>12 hours post-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.33</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>24 hours post-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.05</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>48 hours post-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.83</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunoglobulin Concentration in Chest Tube Drainage</title>
        <description>Immunoglobulin concentration will be measured from chest tube every 4 hours for first 12 hours post-operative and then 24 hours post-operative.</description>
        <time_frame>24 hours post-op</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IVIG</title>
            <description>Those randomized to the study arm will receive a dose of IVIG 1 gram/kg at 12 hours post-cardiopulmonary bypass. This is a one time only dose.
IVIG: Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Subject's randomized into the placebo arm of the study will receive a volume of normal saline that is comparative to that if they were to receive IVIG. This will be at 12 hours post-cardiopulmonary bypass. This volume is to ensure blinding of study drug.
Placebo: If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.</description>
          </group>
        </group_list>
        <measure>
          <title>Immunoglobulin Concentration in Chest Tube Drainage</title>
          <description>Immunoglobulin concentration will be measured from chest tube every 4 hours for first 12 hours post-operative and then 24 hours post-operative.</description>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 hr post-op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.9" lower_limit="23.3" upper_limit="73.6"/>
                    <measurement group_id="O2" value="62.2" lower_limit="39.4" upper_limit="117.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hr post-op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154.3" lower_limit="79.4" upper_limit="250.7"/>
                    <measurement group_id="O2" value="161.3" lower_limit="111" upper_limit="291.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hr post-op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195.2" lower_limit="122.3" upper_limit="308.6"/>
                    <measurement group_id="O2" value="227.6" lower_limit="150.6" upper_limit="448.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hr post-op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="233.5" lower_limit="155.3" upper_limit="316.3"/>
                    <measurement group_id="O2" value="226.8" lower_limit="202.4" upper_limit="447.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hr post-op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="614.2" lower_limit="471" upper_limit="916.4"/>
                    <measurement group_id="O2" value="268.7" lower_limit="190.1" upper_limit="578"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>0 hour levels</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.27</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>4 hour level</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.34</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>8 hour level</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.14</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>12 hour level</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.13</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>24 hour level</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.02</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality</title>
        <description>Incidence of mortality from admit to Pediatric cardiac intensive care unit post-operatively until hospital discharge .</description>
        <time_frame>Approximately 1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IVIG</title>
            <description>Those randomized to the study arm will receive a dose of IVIG 1 gram/kg at 12 hours post-cardiopulmonary bypass. This is a one time only dose.
IVIG: Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Subject's randomized into the placebo arm of the study will receive a volume of normal saline that is comparative to that if they were to receive IVIG. This will be at 12 hours post-cardiopulmonary bypass. This volume is to ensure blinding of study drug.
Placebo: If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality</title>
          <description>Incidence of mortality from admit to Pediatric cardiac intensive care unit post-operatively until hospital discharge .</description>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation.</non_inferiority_desc>
            <p_value>1</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensive Care Unit Length of Stay</title>
        <description>The length of stay in the pediatric cardiac intensive care unit from admit post-operative until either discharge home, discharge to another unit/hospital/care facility, or death. This value is calculated in hours. Admit post-operative is recorded as hour 0.</description>
        <time_frame>1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IVIG</title>
            <description>Those randomized to the study arm will receive a dose of IVIG 1 gram/kg at 12 hours post-cardiopulmonary bypass. This is a one time only dose.
IVIG: Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Subject's randomized into the placebo arm of the study will receive a volume of normal saline that is comparative to that if they were to receive IVIG. This will be at 12 hours post-cardiopulmonary bypass. This volume is to ensure blinding of study drug.
Placebo: If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.</description>
          </group>
        </group_list>
        <measure>
          <title>Intensive Care Unit Length of Stay</title>
          <description>The length of stay in the pediatric cardiac intensive care unit from admit post-operative until either discharge home, discharge to another unit/hospital/care facility, or death. This value is calculated in hours. Admit post-operative is recorded as hour 0.</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="357.9" lower_limit="141.3" upper_limit="536.6"/>
                    <measurement group_id="O2" value="189.6" lower_limit="106.0" upper_limit="575.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation.</non_inferiority_desc>
            <p_value>0.4</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fluid Overload Variables</title>
        <description>The following fluid overload variables will be assessed at 0-24 hours, 25-48 hours, and 0-48 hours post-cardiopulmonary bypass: blood product and albumin administration, chest tube output, urine output, peritoneal dialysis output, net fluid balance, and percent fluid overload.The total output the subject's produce (urine, chest tube, peritoneal drainage, etc.) will be subtracted from the total input (medications, blood products, albumin administration, etc) to determine the total fluid intake in milliliters. This total number will then be divided by the subject's weight in kilograms to determine the fluid overload in mL/kg.</description>
        <time_frame>0-48 hours post-CPB</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IVIG</title>
            <description>Those randomized to the study arm will receive a dose of IVIG 1 gram/kg at 12 hours post-cardiopulmonary bypass. This is a one time only dose.
IVIG: Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Subject's randomized into the placebo arm of the study will receive a volume of normal saline that is comparative to that if they were to receive IVIG. This will be at 12 hours post-cardiopulmonary bypass. This volume is to ensure blinding of study drug.
Placebo: If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.</description>
          </group>
        </group_list>
        <measure>
          <title>Fluid Overload Variables</title>
          <description>The following fluid overload variables will be assessed at 0-24 hours, 25-48 hours, and 0-48 hours post-cardiopulmonary bypass: blood product and albumin administration, chest tube output, urine output, peritoneal dialysis output, net fluid balance, and percent fluid overload.The total output the subject's produce (urine, chest tube, peritoneal drainage, etc.) will be subtracted from the total input (medications, blood products, albumin administration, etc) to determine the total fluid intake in milliliters. This total number will then be divided by the subject's weight in kilograms to determine the fluid overload in mL/kg.</description>
          <units>militers/kilogram</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0-24 hours post-CPB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="0.6" upper_limit="74"/>
                    <measurement group_id="O2" value="58.1" lower_limit="34.4" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25-48 hours post-CPB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" lower_limit="-35.53" upper_limit="41.55"/>
                    <measurement group_id="O2" value="34.9" lower_limit="-0.4" upper_limit="43.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0-48 hours post-CPB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.6" lower_limit="13.9" upper_limit="85.25"/>
                    <measurement group_id="O2" value="77" lower_limit="36.8" upper_limit="114.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>0-48 hours post-CPB</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation.</non_inferiority_desc>
            <p_value>0.09</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>0-24 hours post CPB</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation.</non_inferiority_desc>
            <p_value>0.52</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Respiratory Variables</title>
        <description>Time until first extubation in hours</description>
        <time_frame>until extubation, an average of 2 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IVIG</title>
            <description>Those randomized to the study arm will receive a dose of IVIG 1 gram/kg at 12 hours post-cardiopulmonary bypass. This is a one time only dose.
IVIG: Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Subject's randomized into the placebo arm of the study will receive a volume of normal saline that is comparative to that if they were to receive IVIG. This will be at 12 hours post-cardiopulmonary bypass. This volume is to ensure blinding of study drug.
Placebo: If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.</description>
          </group>
        </group_list>
        <measure>
          <title>Respiratory Variables</title>
          <description>Time until first extubation in hours</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" lower_limit="18.5" upper_limit="88.1"/>
                    <measurement group_id="O2" value="43" lower_limit="18" upper_limit="93.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation.</non_inferiority_desc>
            <p_value>0.72</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Respiratory Variables</title>
        <description>Total time duration of post-operative length of mechanical ventilation until hospital discharge</description>
        <time_frame>until extubation, an average of 2 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IVIG</title>
            <description>Those randomized to the study arm will receive a dose of IVIG 1 gram/kg at 12 hours post-cardiopulmonary bypass. This is a one time only dose.
IVIG: Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Subject's randomized into the placebo arm of the study will receive a volume of normal saline that is comparative to that if they were to receive IVIG. This will be at 12 hours post-cardiopulmonary bypass. This volume is to ensure blinding of study drug.
Placebo: If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.</description>
          </group>
        </group_list>
        <measure>
          <title>Respiratory Variables</title>
          <description>Total time duration of post-operative length of mechanical ventilation until hospital discharge</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.1" lower_limit="29.9" upper_limit="165"/>
                    <measurement group_id="O2" value="59" lower_limit="23.3" upper_limit="153.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation.</non_inferiority_desc>
            <p_value>0.63</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interleukin-10 Plasma Cytokine Levels</title>
        <description>Plasma cytokine levels measured preoperatively, 0, 4, 12, 24 hours, and 48 hours post-operatively.</description>
        <time_frame>pre-operative through 48 hours post-operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IVIG</title>
            <description>Those randomized to the study arm will receive a dose of IVIG 1 gram/kg at 12 hours post-cardiopulmonary bypass. This is a one time only dose.
IVIG: Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Subject's randomized into the placebo arm of the study will receive a volume of normal saline that is comparative to that if they were to receive IVIG. This will be at 12 hours post-cardiopulmonary bypass. This volume is to ensure blinding of study drug.
Placebo: If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin-10 Plasma Cytokine Levels</title>
          <description>Plasma cytokine levels measured preoperatively, 0, 4, 12, 24 hours, and 48 hours post-operatively.</description>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-operative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="1" upper_limit="3.2"/>
                    <measurement group_id="O2" value="1.8" lower_limit="1.1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 hour post-operative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.4" lower_limit="37.5" upper_limit="91.7"/>
                    <measurement group_id="O2" value="124" lower_limit="52.5" upper_limit="216.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hour post-operative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" lower_limit="6.4" upper_limit="25.3"/>
                    <measurement group_id="O2" value="20.1" lower_limit="7.9" upper_limit="56.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hour post-operative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" lower_limit="2.7" upper_limit="7.9"/>
                    <measurement group_id="O2" value="10.2" lower_limit="5.5" upper_limit="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hour post-operative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="1.2" upper_limit="3.6"/>
                    <measurement group_id="O2" value="4" lower_limit="2" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hour post-operatiave</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0.8" upper_limit="2.3"/>
                    <measurement group_id="O2" value="2.3" lower_limit="1.2" upper_limit="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>pre-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation.</non_inferiority_desc>
            <p_value>0.41</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>0 hour post-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.34</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>4 hour post-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.47</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>12 hour post-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.42</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>24 hour post-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.82</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>48 hour post-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.44</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interleukin-12p70 Plasma Cytokine Levels</title>
        <description>Plasma cytokine levels measured preoperatively, 0, 4, 12, 24 hours, and 48 hours post-operatively.</description>
        <time_frame>pre-operative through 48 hours post-operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IVIG</title>
            <description>Those randomized to the study arm will receive a dose of IVIG 1 gram/kg at 12 hours post-cardiopulmonary bypass. This is a one time only dose.
IVIG: Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Subject's randomized into the placebo arm of the study will receive a volume of normal saline that is comparative to that if they were to receive IVIG. This will be at 12 hours post-cardiopulmonary bypass. This volume is to ensure blinding of study drug.
Placebo: If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin-12p70 Plasma Cytokine Levels</title>
          <description>Plasma cytokine levels measured preoperatively, 0, 4, 12, 24 hours, and 48 hours post-operatively.</description>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-operative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0.2" upper_limit="0.2"/>
                    <measurement group_id="O2" value="0.2" lower_limit="0.2" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 hour post-operative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0.2" upper_limit="0.3"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.3" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hour post-operative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0.3" upper_limit="0.5"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.3" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hour post-operative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.3" upper_limit="0.8"/>
                    <measurement group_id="O2" value="1" lower_limit="0.4" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hour post-operative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.2" upper_limit="0.5"/>
                    <measurement group_id="O2" value="0.7" lower_limit="0.3" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hour post-operatiave</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0.2" upper_limit="0.3"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0.2" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>pre-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation.</non_inferiority_desc>
            <p_value>0.28</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>0 hour post-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.37</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>4 hour post-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.42</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>12 hour post-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.31</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>24 hour post-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.38</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>48 hour post-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.4</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interleukin-1b Plasma Cytokine Levels</title>
        <description>Plasma cytokine levels measured preoperatively, 0, 4, 12, 24 hours, and 48 hours post-operatively.</description>
        <time_frame>pre-operative through 48 hours post-operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IVIG</title>
            <description>Those randomized to the study arm will receive a dose of IVIG 1 gram/kg at 12 hours post-cardiopulmonary bypass. This is a one time only dose.
IVIG: Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Subject's randomized into the placebo arm of the study will receive a volume of normal saline that is comparative to that if they were to receive IVIG. This will be at 12 hours post-cardiopulmonary bypass. This volume is to ensure blinding of study drug.
Placebo: If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin-1b Plasma Cytokine Levels</title>
          <description>Plasma cytokine levels measured preoperatively, 0, 4, 12, 24 hours, and 48 hours post-operatively.</description>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-operative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0.1" upper_limit="0.2"/>
                    <measurement group_id="O2" value="0.2" lower_limit="0.1" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 hour post-operative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.2" upper_limit="0.4"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0.3" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hour post-operative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.3" upper_limit="0.6"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.4" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hour post-operative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.3" upper_limit="0.5"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.2" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hour post-operative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.2" upper_limit="0.5"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.3" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hour post-operatiave</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.2" upper_limit="0.6"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.2" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>pre-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation.</non_inferiority_desc>
            <p_value>0.1</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>0 hour post-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.12</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>4 hour post-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.51</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>12 hour post-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.27</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>24 hour post-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.88</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>48 hour post-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.38</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interleukin-6 Plasma Cytokine Levels</title>
        <description>Plasma cytokine levels measured preoperatively, 0, 4, 12, 24 hours, and 48 hours post-operatively.</description>
        <time_frame>pre-operative through 48 hours post-operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IVIG</title>
            <description>Those randomized to the study arm will receive a dose of IVIG 1 gram/kg at 12 hours post-cardiopulmonary bypass. This is a one time only dose.
IVIG: Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Subject's randomized into the placebo arm of the study will receive a volume of normal saline that is comparative to that if they were to receive IVIG. This will be at 12 hours post-cardiopulmonary bypass. This volume is to ensure blinding of study drug.
Placebo: If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin-6 Plasma Cytokine Levels</title>
          <description>Plasma cytokine levels measured preoperatively, 0, 4, 12, 24 hours, and 48 hours post-operatively.</description>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-operative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="1.1" upper_limit="5.5"/>
                    <measurement group_id="O2" value="3.3" lower_limit="1.4" upper_limit="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 hour post-operative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" lower_limit="6.6" upper_limit="16.2"/>
                    <measurement group_id="O2" value="17.3" lower_limit="9.9" upper_limit="30.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hour post-operative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.6" lower_limit="23.6" upper_limit="46.5"/>
                    <measurement group_id="O2" value="52.4" lower_limit="33.8" upper_limit="84.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hour post-operative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.6" lower_limit="29.6" upper_limit="64.8"/>
                    <measurement group_id="O2" value="49.8" lower_limit="36.6" upper_limit="86.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hour post-operative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.3" lower_limit="15.6" upper_limit="50.4"/>
                    <measurement group_id="O2" value="40.8" lower_limit="24.2" upper_limit="81.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hour post-operatiave</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" lower_limit="9.4" upper_limit="21.5"/>
                    <measurement group_id="O2" value="15.5" lower_limit="10.5" upper_limit="24.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>pre-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation.</non_inferiority_desc>
            <p_value>0.35</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>0 hour post-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.39</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>4 hour post-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.58</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>12 hour post-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.36</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>24 hour post-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.61</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>48 hour post-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.38</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interleukin-8 Plasma Cytokine Levels</title>
        <description>Plasma cytokine levels measured preoperatively, 0, 4, 12, 24 hours, and 48 hours post-operatively.</description>
        <time_frame>pre-operative through 48 hours post-operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IVIG</title>
            <description>Those randomized to the study arm will receive a dose of IVIG 1 gram/kg at 12 hours post-cardiopulmonary bypass. This is a one time only dose.
IVIG: Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Subject's randomized into the placebo arm of the study will receive a volume of normal saline that is comparative to that if they were to receive IVIG. This will be at 12 hours post-cardiopulmonary bypass. This volume is to ensure blinding of study drug.
Placebo: If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin-8 Plasma Cytokine Levels</title>
          <description>Plasma cytokine levels measured preoperatively, 0, 4, 12, 24 hours, and 48 hours post-operatively.</description>
          <units>pg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-operative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" lower_limit="14.4" upper_limit="22.7"/>
                    <measurement group_id="O2" value="17.7" lower_limit="12.8" upper_limit="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 hour post-operative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.5" lower_limit="58.8" upper_limit="131"/>
                    <measurement group_id="O2" value="163" lower_limit="99.9" upper_limit="255.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hour post-operative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.5" lower_limit="63.6" upper_limit="162.3"/>
                    <measurement group_id="O2" value="147.5" lower_limit="71" upper_limit="214.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hour post-operative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.1" lower_limit="36.7" upper_limit="131"/>
                    <measurement group_id="O2" value="90" lower_limit="50" upper_limit="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hour post-operative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.7" lower_limit="40.3" upper_limit="61.7"/>
                    <measurement group_id="O2" value="46" lower_limit="33.4" upper_limit="112.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hour post-operatiave</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.6" lower_limit="24.6" upper_limit="59.8"/>
                    <measurement group_id="O2" value="38.2" lower_limit="23.6" upper_limit="64.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>pre-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation.</non_inferiority_desc>
            <p_value>0.1</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>0 hour post-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.02</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>4 hour post-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.34</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>12 hour post-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.35</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>24 hour post-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.67</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>48 hour post-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.47</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tumor Necrosis Factor Plasma Cytokine Levels</title>
        <description>Plasma cytokine levels measured preoperatively, 0, 4, 12, 24 hours, and 48 hours post-operatively.</description>
        <time_frame>pre-operative through 48 hours post-operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IVIG</title>
            <description>Those randomized to the study arm will receive a dose of IVIG 1 gram/kg at 12 hours post-cardiopulmonary bypass. This is a one time only dose.
IVIG: Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Subject's randomized into the placebo arm of the study will receive a volume of normal saline that is comparative to that if they were to receive IVIG. This will be at 12 hours post-cardiopulmonary bypass. This volume is to ensure blinding of study drug.
Placebo: If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Necrosis Factor Plasma Cytokine Levels</title>
          <description>Plasma cytokine levels measured preoperatively, 0, 4, 12, 24 hours, and 48 hours post-operatively.</description>
          <units>pg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-operative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="1.9" upper_limit="3.4"/>
                    <measurement group_id="O2" value="2.9" lower_limit="2.4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 hour post-operative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="2.2" upper_limit="3.8"/>
                    <measurement group_id="O2" value="4.3" lower_limit="2.5" upper_limit="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hour post-operative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" lower_limit="2.6" upper_limit="5.6"/>
                    <measurement group_id="O2" value="5.3" lower_limit="3.7" upper_limit="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hour post-operative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" lower_limit="2.2" upper_limit="3.4"/>
                    <measurement group_id="O2" value="4.1" lower_limit="2.7" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hour post-operative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="2.2" upper_limit="3.4"/>
                    <measurement group_id="O2" value="3.8" lower_limit="3" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hour post-operatiave</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="2" upper_limit="3.2"/>
                    <measurement group_id="O2" value="3.5" lower_limit="2.1" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>pre-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.46</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>0 hour post-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.04</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>4 hour post-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.14</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>12 hour post-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.82</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>24 hour post-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.9</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>48 hour post-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.78</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunoglobulin Concentration in Peritoneal Dialysis Drainage</title>
        <description>Immunoglobulin concentration will be measured from chest tube and peritoneal drain every 4 hours for first 12 hours post-operative and 24 hours post-operative.</description>
        <time_frame>24 hours post-op</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IVIG</title>
            <description>Those randomized to the study arm will receive a dose of IVIG 1 gram/kg at 12 hours post-cardiopulmonary bypass. This is a one time only dose.
IVIG: Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Subject's randomized into the placebo arm of the study will receive a volume of normal saline that is comparative to that if they were to receive IVIG. This will be at 12 hours post-cardiopulmonary bypass. This volume is to ensure blinding of study drug.
Placebo: If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.</description>
          </group>
        </group_list>
        <measure>
          <title>Immunoglobulin Concentration in Peritoneal Dialysis Drainage</title>
          <description>Immunoglobulin concentration will be measured from chest tube and peritoneal drain every 4 hours for first 12 hours post-operative and 24 hours post-operative.</description>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 hr post-op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.1" lower_limit="18.8" upper_limit="52.1"/>
                    <measurement group_id="O2" value="101.6" lower_limit="11.5" upper_limit="144.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hr post-op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136.2" lower_limit="45.6" upper_limit="263.3"/>
                    <measurement group_id="O2" value="201.6" lower_limit="114.5" upper_limit="384.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hr post-op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="279.8" lower_limit="193.4" upper_limit="446.8"/>
                    <measurement group_id="O2" value="221.2" lower_limit="84.4" upper_limit="513.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hr post-op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="387.33" lower_limit="143.1" upper_limit="510.2"/>
                    <measurement group_id="O2" value="300.1" lower_limit="149.4" upper_limit="434.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hr post-op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1613.9" lower_limit="598.3" upper_limit="2181.1"/>
                    <measurement group_id="O2" value="366.9" lower_limit="170.4" upper_limit="984.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>0 hour level</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation.</non_inferiority_desc>
            <p_value>0.37</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>4 hour level</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.47</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>8 hour level</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.47</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>12 hour level</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.79</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>24 hour level</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.04</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Creatinine</title>
        <description>Pre-operative and 48 hour post-operative maximum creatinine recorded.</description>
        <time_frame>48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IVIG</title>
            <description>Those randomized to the study arm will receive a dose of IVIG 1 gram/kg at 12 hours post-cardiopulmonary bypass. This is a one time only dose.
IVIG: Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Subject's randomized into the placebo arm of the study will receive a volume of normal saline that is comparative to that if they were to receive IVIG. This will be at 12 hours post-cardiopulmonary bypass. This volume is to ensure blinding of study drug.
Placebo: If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Creatinine</title>
          <description>Pre-operative and 48 hour post-operative maximum creatinine recorded.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-operative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.15"/>
                    <measurement group_id="O2" value="0.4" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Max</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.28"/>
                    <measurement group_id="O2" value="0.7" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>pre-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation.</non_inferiority_desc>
            <p_value>0.43</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>max</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.68</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lactic Acid</title>
        <time_frame>pre-operative through 24 hours post-operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IVIG</title>
            <description>Those randomized to the study arm will receive a dose of IVIG 1 gram/kg at 12 hours post-cardiopulmonary bypass. This is a one time only dose.
IVIG: Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Subject's randomized into the placebo arm of the study will receive a volume of normal saline that is comparative to that if they were to receive IVIG. This will be at 12 hours post-cardiopulmonary bypass. This volume is to ensure blinding of study drug.
Placebo: If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.</description>
          </group>
        </group_list>
        <measure>
          <title>Lactic Acid</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-operative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.65"/>
                    <measurement group_id="O2" value="1.4" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hour maximum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="4"/>
                    <measurement group_id="O2" value="5.4" spread="4.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>pre-operative</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation.</non_inferiority_desc>
            <p_value>0.87</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>24 hour post-operative max</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations were not performed on this statistical calculation</non_inferiority_desc>
            <p_value>0.79</p_value>
            <p_value_desc>A p-value of &lt;0.05 represents the threshold for statistical significance</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>IVIG</title>
          <description>Those randomized to the study arm will receive a dose of IVIG 1 gram/kg at 12 hours post-cardiopulmonary bypass. This is a one time only dose.
IVIG: Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.</description>
        </group>
        <group group_id="E2">
          <title>Normal Saline</title>
          <description>Subject's randomized into the placebo arm of the study will receive a volume of normal saline that is comparative to that if they were to receive IVIG. This will be at 12 hours post-cardiopulmonary bypass. This volume is to ensure blinding of study drug.
Placebo: If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jeffrey Alten, MD</name_or_title>
      <organization>UAB Pediatric Cardiac Critical Care Medicine</organization>
      <phone>(205) 975-3123</phone>
      <email>jalten@peds.uab.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

